The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.
The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.